News Release

Cleanascite™ Employed to Determine Role of Lipids in Neutrophil Trafficking to Infection Sites

MONMOUTH JUNCTION, NJ, December 19, 2022 -- Biotech Support Group reports on an article, describing their lipid clearance sample preparation technology to help determine the role of fatty acid oxidation and mitochondrial metabolism in a cell response study of murine cell culture models of susceptibility to infection. The citation is:

Pham, Ly, et al. "Neutrophil trafficking to the site of infection requires Cpt1a-dependent fatty acid β-oxidation." Communications Biology 5.1 (2022): 1-13.

Carnitine palmitoyltransferase 1a (Cpt1a) is considered the rate-limiting enzyme for mitochondrial metabolism of long-chain fatty acids, and Cpt1a deficiency is associated with infant mortality and infection risk. This study was undertaken to test the hypothesis that impairment in Cpt1a-dependent fatty acid oxidation results in increased susceptibility to infection. The article states for lipid depletion “…cells were incubated with RPMI containing 0.5% FBS or with 10% FBS that had been treated with Cleanascite (Biotech Support Group) to remove lipids”. Observations were made that manipulation of exogenous free fatty acids, either through the depletion of lipids from the culture medium or through the addition of exogenous octanoic acid, alters neutrophil chemotactic functions. The article concludes that susceptibility to pneumonia is associated with blunted neutrophilic responses in mice and humans that result from impaired neutrophil trafficking to the site of infection. Chemotaxis responsible for neutrophil trafficking requires Cpt1a-dependent mitochondrial fatty acid oxidation for amplification of chemoattractant signals. These findings identify Cpt1a as a potential host determinant of infection susceptibility and demonstrate a requirement for mitochondrial fatty acid oxidation in neutrophil biology. 

“We now have over twenty references, showing that Cleanascite™ was used to help identify a characteristic feature of in vitro cell response. Unlike alternative lipid-depletion methods that use solvents, Cleanascite™ is an aqueous suspension product and so it is very compatible with cellular models of disease. This ultimately helps with investigations such as this, whereby the cells require fetal bovine serum for growth, but the exogenous lipids need to be removed in order to determine their phenotypic effect.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

To download whitepaper entitled “Cleanascite™ - Lipid Removal and Cell Response Applications”, visit:

https://www.biotechsupportgroup.com/v/vspfiles/templates/257/pdf/CleanasciteCellResponseReferenceApplications113021.pdf

For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm

Keywords

Carnitine palmitoyltransferase 1a (Cpt1a), Neutrophil trafficking, Neutrophil chemotaxis, Cleanascite™, lipid depletion, mitochondrial fatty acid oxidation, microbial infection susceptibility

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com.

For Business Development, contact: Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com